Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)

This study is testing whether adding targeted radiation therapy after an initial course of the drug alectinib can improve outcomes for people with advanced non-small cell lung cancer (NSCLC) that has a specific genetic change called an ALK rearrangement. The idea is that alectinib shrinks the tumor first, then radiation cleans up what's left. **You may be eligible if...** - You have been diagnosed with advanced or recurrent NSCLC - Your cancer has an ALK gene rearrangement - Your disease was stable or improved after 2–3 months of alectinib - You have 5 or fewer active tumor spots that can be targeted with radiation **You may NOT be eligible if...** - Your cancer does not have an ALK rearrangement - Your cancer is still growing despite alectinib - Your tumors cannot safely be treated with focused radiation Talk to your doctor to see if this trial is right for you.